Cambridge startup biotechnology company Walden Biosciences announced its launch today with a $51 million Series A financing led by UCB Ventures and ARCH Venture Partners. Walden is seeking to develop breakthrough therapies to treat rare and common forms of kidney disease affecting more than 1 in 7 American adults.

Links to related news articles here: